Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1997 Jan;90(1):121–128. doi: 10.1046/j.1365-2567.1997.00120.x

Binding of human and rat CD59 to the terminal complement complexes.

T Lehto 1, B P Morgan 1, S Meri 1
PMCID: PMC1456727  PMID: 9038722

Abstract

CD59-antigen (protectin) is a widely distributed glycolipid-anchored inhibitor of complement lysis. CD59 interacts with complement components C8 and C9 during assembly of the membrane attack complex (MAC). To evaluate species specificity of these interactions we have in the present study examined cross-species binding of isolated human and rat CD59 to the terminal complement components C8 and C9. By using primarily soluble CD59 isolated from urine (CD59U) potentially non-specific binding interactions of the phospholipid portion of the membrane forms of CD59 could be avoided. Sucrose density gradient ultracentrifugation analysis showed that human CD59U bound to both human and rat C8 in the SC5b-8 complexes. Similar binding occurred when rat CD59U was used. The degree of binding did not significantly differ between the heterologous and homologous CD59-C8 combinations. C9 from both species inhibited the binding of CD59 to soluble SC5b-8. In ligand blotting analysis human and rat CD59U bound to human and rat C8 alpha gamma-subunit and C9. Binding of human and rat CD59U was stronger to human than rat C9. In plate binding assays the erythrocyte form of CD59 (CD59E) bound to both human and rat C8. Binding of CD59E to heterologous C9 was considerably weaker than to homologous C9. Our results imply that the reciprocal binding sites between C8 and CD59 and to a lesser degree between CD59 and C9 are conserved between human and rat. Interactions of CD59 with the terminal C components are thus species selective but not 'homologously restricted'.

Full text

PDF
121

Images in this article

125Figure 4
on p.125
125Figure 5
on p.125

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraha A., Morgan B. P., Luzio J. P. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J. 1988 Apr 1;251(1):285–292. doi: 10.1042/bj2510285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brooimans R. A., Van der Ark A. A., Tomita M., Van Es L. A., Daha M. R. CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis. Eur J Immunol. 1992 Mar;22(3):791–797. doi: 10.1002/eji.1830220324. [DOI] [PubMed] [Google Scholar]
  3. Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989 Sep 1;170(3):637–654. doi: 10.1084/jem.170.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fletcher C. M., Harrison R. A., Lachmann P. J., Neuhaus D. Sequence-specific 1H-NMR assignments and folding topology of human CD59. Protein Sci. 1993 Dec;2(12):2015–2027. doi: 10.1002/pro.5560021203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fodor W. L., Rollins S. A., Bianco-Caron S., Burton W. V., Guilmette E. R., Rother R. P., Zavoico G. B., Squinto S. P. Primate terminal complement inhibitor homologues of human CD59. Immunogenetics. 1995;41(1):51–51. doi: 10.1007/BF00188435. [DOI] [PubMed] [Google Scholar]
  6. Harada R., Okada N., Fujita T., Okada H. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. J Immunol. 1990 Mar 1;144(5):1823–1828. [PubMed] [Google Scholar]
  7. Holguin M. H., Fredrick L. R., Bernshaw N. J., Wilcox L. A., Parker C. J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989 Jul;84(1):7–17. doi: 10.1172/JCI114172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hüsler T., Lockert D. H., Kaufman K. M., Sodetz J. M., Sims P. J. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59. J Biol Chem. 1995 Feb 24;270(8):3483–3486. doi: 10.1074/jbc.270.8.3483. [DOI] [PubMed] [Google Scholar]
  9. Jones J., Laffafian I., Morgan B. P. Purification of C8 and C9 from rat serum. Complement Inflamm. 1990;7(1):42–51. doi: 10.1159/000463125. [DOI] [PubMed] [Google Scholar]
  10. Kieffer B., Driscoll P. C., Campbell I. D., Willis A. C., van der Merwe P. A., Davis S. J. Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins. Biochemistry. 1994 Apr 19;33(15):4471–4482. [PubMed] [Google Scholar]
  11. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  12. Lehto T., Meri S. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8. J Immunol. 1993 Nov 1;151(9):4941–4949. [PubMed] [Google Scholar]
  13. Meri S., Lehto T., Sutton C. W., Tyynelä J., Baumann M. Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem J. 1996 Jun 15;316(Pt 3):923–935. doi: 10.1042/bj3160923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Meri S., Mattila P., Renkonen R. Regulation of CD59 expression on the human endothelial cell line EA.hy 926. Eur J Immunol. 1993 Oct;23(10):2511–2516. doi: 10.1002/eji.1830231020. [DOI] [PubMed] [Google Scholar]
  15. Meri S., Waldmann H., Lachmann P. J. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest. 1991 Nov;65(5):532–537. [PubMed] [Google Scholar]
  16. Monahan J. B., Sodetz J. M. Role of the beta subunit in interaction of the eighth component of human complement with the membrane-bound cytolytic complex. J Biol Chem. 1981 Apr 10;256(7):3258–3262. [PubMed] [Google Scholar]
  17. Morgan B. P., Daw R. A., Siddle K., Luzio J. P., Campbell A. K. Immunoaffinity purification of human complement component C9 using monoclonal antibodies. J Immunol Methods. 1983 Nov 25;64(3):269–281. doi: 10.1016/0022-1759(83)90434-9. [DOI] [PubMed] [Google Scholar]
  18. Ninomiya H., Stewart B. H., Rollins S. A., Zhao J., Bothwell A. L., Sims P. J. Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity. J Biol Chem. 1992 Apr 25;267(12):8404–8410. [PubMed] [Google Scholar]
  19. Nose M., Katoh M., Okada N., Kyogoku M., Okada H. Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology. 1990 Jun;70(2):145–149. [PMC free article] [PubMed] [Google Scholar]
  20. Okada N., Harada R., Fujita T., Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol. 1989;1(2):205–208. doi: 10.1093/intimm/1.2.205. [DOI] [PubMed] [Google Scholar]
  21. Rollins S. A., Sims P. J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990 May 1;144(9):3478–3483. [PubMed] [Google Scholar]
  22. Rollins S. A., Zhao J., Ninomiya H., Sims P. J. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol. 1991 Apr 1;146(7):2345–2351. [PubMed] [Google Scholar]
  23. Rushmere N. K., Harrison R. A., van den Berg C. W., Morgan B. P. Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem J. 1994 Dec 1;304(Pt 2):595–601. doi: 10.1042/bj3040595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sugita Y., Nakano Y., Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem. 1988 Oct;104(4):633–637. doi: 10.1093/oxfordjournals.jbchem.a122524. [DOI] [PubMed] [Google Scholar]
  25. Takizawa H., Takahashi K., Murakami T., Okada N., Okada H. Species-specific restriction of complement by HRF20 (CD59) generated by cDNA transfection. Eur J Immunol. 1992 Jul;22(7):1943–1946. doi: 10.1002/eji.1830220741. [DOI] [PubMed] [Google Scholar]
  26. Tedesco F., Bardare M., Giovanetti A. M., Sirchia G. A familial dysfunction of the eight component of complement (C8). Clin Immunol Immunopathol. 1980 Jun;16(2):180–191. doi: 10.1016/0090-1229(80)90202-0. [DOI] [PubMed] [Google Scholar]
  27. Tedesco F. Component deficiencies. 8. The eighth component. Prog Allergy. 1986;39:295–306. [PubMed] [Google Scholar]
  28. Tedesco F., Densen P., Villa M. A., Petersen B. H., Sirchia G. Two types of dysfunctional eighth component of complement (C8) molecules in C8 deficiency in man. Reconstitution of normal C8 from the mixture of two abnormal C8 molecules. J Clin Invest. 1983 Feb;71(2):183–191. doi: 10.1172/JCI110758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tomlinson S., Wang Y., Ueda E., Esser A. F. Chimeric horse/human recombinant C9 proteins identify the amino acid sequence in horse C9 responsible for restriction of hemolysis. J Immunol. 1995 Jul 1;155(1):436–444. [PubMed] [Google Scholar]
  30. Tschopp J., Esser A. F., Spira T. J., Müller-Eberhard H. J. Occurrence of an incomplete C8 molecule in homozygous C8 deficiency in man. J Exp Med. 1981 Nov 1;154(5):1599–1607. doi: 10.1084/jem.154.5.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Väkevä A., Laurila P., Meri S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest. 1992 Nov;67(5):608–616. [PubMed] [Google Scholar]
  32. White R. V., Kaufman K. M., Letson C. S., Platteborze P. L., Sodetz J. M. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59). J Immunol. 1994 Mar 1;152(5):2501–2508. [PubMed] [Google Scholar]
  33. van den Berg C. W., Morgan B. P. Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J Immunol. 1994 Apr 15;152(8):4095–4101. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES